Strontium ranelate
- Generic Name
- Strontium ranelate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H6N2O8SSr2
- CAS Number
- 135459-87-9
- Unique Ingredient Identifier
- 04NQ160FRU
- Background
Strontium ranelate, a strontium (II) salt of ranelic acid, is a medication for osteoporosis. Some reports have shown that strontium ranelate can slow down the progression of osteoarthritis of the knee. This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of...
- Indication
Strontium ranelate is therapeutically indicated for the treatment of severe osteoperosis in: a) postmenopasual women, and b) adult men, who are at high risk of fractures, for whom treatment with other medical products approved for the treatment of osteoperosis is not possible due to, for example, contraindications or intolerance.
...
- Associated Conditions
- Severe Osteoporosis
- Associated Therapies
- -
Role of Strontium Ranelate in Proximal Femur Fragility Fractures.
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Aga Khan University Hospital, Pakistan
- Target Recruit Count
- 100
- Registration Number
- NCT05712616
- Locations
- 🇵🇰
Aga Khan University Hospital, Karachi, Sindh, Pakistan
Strontium Ranelate and KOA
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 30
- Registration Number
- NCT03937518
- Locations
- 🇪🇬
Mansoura Uninersity Faculty of Medicine, Mansoura, Dakahlia Provence, Egypt
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- University of Valencia
- Target Recruit Count
- 80
- Registration Number
- NCT01544894
- Locations
- 🇪🇸
Hospital Universitario Dr Peset, Valencia, Spain
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
- Conditions
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Nycomed
- Target Recruit Count
- 82
- Registration Number
- NCT00479037
- Locations
- 🇩🇰
Nycomed, Roskilde, Denmark
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 73
- Registration Number
- NCT00239629
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.